Sector: Healthcare | Industry: Pharmaceuticals |
Company Contact | |
Address: | 595 Burrard Street, Suite 3123 VANCOUVER BC V7X 1J1 |
Tel: | N/A |
Website: | https://core1labs.com |
IR: | See website |
Key People | ||
Joel Shacker Chief Executive Officer, Director | Geoffrey Balderson Chief Financial Officer, Corporate Secretary, Director |
Business Overview |
Core One Labs Inc. is a Canada-based life sciences biotechnology research and development company. The Company is focused on bringing psychedelic medicines to market through the development and production of psychedelic compounds, the advancement of psychedelic assisted treatments, and the integration of delivery systems technology. The Company, through its wholly owned subsidiary, Vocan Biotechnologies Inc., has developed and filed for patent protection of a proprietary psilocybin production system using engineered bacteria. It is also the holder of four provisional patents for the development of psychedelic-based pharmaceutical formulations targeting neurological and mental health disorders, under its subsidiary Akome Biotech Ltd., and three provisional patents under its other subsidiary, Awakened Biosciences Inc., for additional synthetic technologies for psilocybin and psilocin production methods. It also holds an interest in four medical clinics. |
Financial Overview |
For the nine months ended 31 December 2023, Core One Labs Inc revenues decreased 48% to C$268K. Net loss decreased 49% to C$2.1M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Share-based payments decrease of 92% to C$272K (expense), Wages and salaries decrease of 62% to C$233K (expense), Transaction expense decrease of 28% to C$411K (expense). |
Reporting Currency: | Canadian Dollars |
Enterprise value: | $10.36M as of Dec 31, 2023 |
Annual revenue (TTM): | N/A |
EBITDA (TTM): | N/A |
Net annual income (TTM): | N/A |
Free cash flow (TTM): | -$1.55M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $0.10M as of Dec 31, 2023 |
Shares outstanding: | 47,097,332 as of Jan 29, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |